The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BJDX | -79.09% | N/A | N/A | -100% |
| S&P | +15.39% | +87.63% | +13.4% | +50% |
Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally-invasive Point-of-Care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focus is on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Dey Indraneil on March 20, 2015 and is headquartered in Acton, MA.
No news articles found for Bluejay Diagnostics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$31.62K | 41.0% |
| Market Cap | $2.49M | 10.0% |
| Market Cap / Employee | $355.93K | 0.0% |
| Employees | 7 | 0.0% |
| Net Income | -$1,597.63K | -7.8% |
| EBITDA | -$1,585.33K | -21.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.08M | -46.4% |
| Accounts Receivable | $0.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $48.56K | -65.2% |
| Short Term Debt | $104.81K | -9.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -103.46% | 0.0% |
| Return On Invested Capital | -39.13% | 21.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,359.79K | 29.6% |
| Operating Free Cash Flow | -$1,359.79K | 29.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.47 | 0.53 | 0.49 | 0.67 | 113.51% |
| Price to Tangible Book Value | 0.97 | 1.44 | 0.99 | 1.72 | -77.39% |
| Enterprise Value to EBITDA | 0.95 | 0.46 | 0.97 | 0.34 | -89.69% |
| Return on Equity | -179.0% | -200.6% | -96.7% | -126.2% | -9.07% |
| Total Debt | $235.62K | $199.76K | $176.77K | $153.37K | -40.09% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
